Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX™ sNDA for the Treatment of Osteoarthritis Pain in ... Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX™ , a lower dose nonsteroidal anti-inflammatory drug , for the proposed indication of treatment of osteoarthritis pain in adults.
Jan. 15, 2014 - Business Wire via Yahoo! Finance